Ge Jie, Chen Zihua, Huang Jin, Yuan Weijie, Den Zhenghao, Chen Zhikang
Department of Gastrointestinal Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China.
Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China.
Mol Med Rep. 2015 Jan;11(1):633-8. doi: 10.3892/mmr.2014.2746. Epub 2014 Oct 22.
The oncoprotein insulin-like growth factor-1 receptor (IGF-1R) has previously been shown to promote tumorigenesis. Overexpression of IGF-1R is considered to be a critical prerequisite for malignant transformation in numerous human cancers. Therefore, targeting IGF-1R for cancer therapy has gained a lot of interest. In the present study, an RNA interference (RNAi)-mediated IGF-1R gene silencing approach was conducted in BGC823 gastric cancer cells. The tumorigenic and malignant properties of the cells were assessed, in response to reduced IGF-1R expression. Notably, IGF-1R depletion not only inhibited gastric cancer cell growth, resulted in G1 cell cycle arrest and consequently led to apoptosis, but also suppressed cancer cell motility and invasion. The findings of the present study are the first, to the best of our knowledge, to suggest that RNAi-based IGF-1R silencing may be a potential and promising therapeutic strategy for gastric cancer treatment.
癌蛋白胰岛素样生长因子-1受体(IGF-1R)先前已被证明可促进肿瘤发生。IGF-1R的过表达被认为是许多人类癌症发生恶性转化的关键先决条件。因此,靶向IGF-1R进行癌症治疗已引起广泛关注。在本研究中,在BGC823胃癌细胞中采用了RNA干扰(RNAi)介导的IGF-1R基因沉默方法。针对IGF-1R表达降低的情况,评估了细胞的致瘤性和恶性特性。值得注意的是,IGF-1R缺失不仅抑制胃癌细胞生长,导致G1期细胞周期停滞并进而导致细胞凋亡,还抑制癌细胞的运动性和侵袭能力。据我们所知,本研究结果首次表明基于RNAi的IGF-1R沉默可能是一种潜在且有前景的胃癌治疗策略。